RT Journal Article
SR Electronic
T1 Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: national cohort study, England
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.15.22271001
DO 10.1101/2022.02.15.22271001
A1 Allen, Hester
A1 Tessier, Elise
A1 Turner, Charlie
A1 Anderson, Charlotte
A1 Blomquist, Paula
A1 Simons, David
A1 Løchen, Alessandra
A1 Jarvis, Christopher I
A1 Groves, Natalie
A1 Capelastegui, Fernando
A1 Flannagan, Joe
A1 Zaidi, Asad
A1 Chen, Cong
A1 Rawlinson, Christopher
A1 Hughes, Gareth J.
A1 Chudasama, Dimple
A1 Nash, Sophie
A1 Thelwall, Simon
A1 Lopez-Bernal, Jamie
A1 Dabrera, Gavin
A1 Charlett, André
A1 Kall, Meaghan
A1 Lamagni, Theresa
YR 2022
UL http://medrxiv.org/content/early/2022/02/17/2022.02.15.22271001.abstract
AB Background The SARS-CoV-2 Omicron variant (B.1.1.529) has rapidly replaced the Delta variant (B.1.617.2) to become dominant in England. This epidemiological study assessed differences in transmissibility between the Omicron and Delta using two methods and data sources.Methods Omicron and Delta cases were identified through genomic sequencing, genotyping and S-gene target failure in England from 5-11 December 2021. Secondary attack rates for Omicron and Delta using named contacts and household clustering were calculated using national surveillance and contact tracing data. We used multivariable logistic regression was used to control for factors associated with transmission.Findings Analysis of contact tracing data identified elevated secondary attack rates for Omicron vs Delta in household (15.0% vs 10.8%) and non-household (8.2% vs 3.7%) settings. The proportion of index cases resulting in residential clustering was twice as high for Omicron (16.1%) compared to Delta (7.3%). Transmission was significantly less likely from cases, or in named contacts, in receipt of three compared to two vaccine doses in household settings, but less pronounced for Omicron (aRR 0.78 and 0.88) compared to Delta (aRR 0.62 and 0.68). In non-household settings, a similar reduction was observed for Delta cases and contacts (aRR 0.84 and 0.51) but only for Omicron contacts (aRR 0.76, 95% CI: 0.58-0.93) and not cases in receipt of three vs two doses (aRR 0.95, 0.77-1.16).Interpretation Our study identified increased risk of onward transmission of Omicron, consistent with its successful global displacement of Delta. We identified a reduced effectiveness of vaccination in lowering risk of transmission, a likely contributor for the rapid propagation of Omicron.Funding Study funded by the UK Health Security Agency.Competing Interest StatementThe authors have declared no competing interest.Funding StatementStudy funded by the UK Health Security Agency.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Thank you for submitting your study to the Research Support and Governance Office (RSGO) for review by the PHE Research Ethics and Governance Group (REGG). PHE approval for your study has been granted and you can now start your work in this organisation. This approval is granted based on the information provided in the REGG application form and accompanying study documentation, and on the understanding that the study is conducted in accordance with the conditions stated in the applicable PHE policies and procedures.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be available upon request.